Get the Stockscreener App
1.32
1.54%
0.02
After Hours:
1.32
Heron Therapeutics Inc stock is traded at $1.32, with a volume of 848.82K.
It is up +1.54% in the last 24 hours and up +4.76% over the past month.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
See More
Previous Close:
$1.30
Open:
$1.28
24h Volume:
848.82K
Relative Volume:
0.51
Market Cap:
$241.98M
Revenue:
$137.74M
Net Income/Loss:
$-27.97M
P/E Ratio:
-8.25
EPS:
-0.16
Net Cash Flow:
$-9.61M
1W Performance:
+0.00%
1M Performance:
+4.76%
6M Performance:
-31.61%
1Y Performance:
-26.26%
1-Day Range:
$1.275
$1.33
1-Week Range:
$1.275
$1.385
52-Week Range:
$1.04
$2.68
Heron Therapeutics Inc Stock (HRTX) Company Profile
Name
Heron Therapeutics Inc
Sector
Industry
Phone
(858) 251-4400
Address
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Compare HRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
1.32 | 238.31M | 137.74M | -27.97M | -9.61M | -0.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-25 | Initiated | H.C. Wainwright | Buy |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-23-24 | Initiated | CapitalOne | Overweight |
| Mar-13-24 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Buy |
| Feb-20-20 | Reiterated | Needham | Buy |
| Jan-16-19 | Reiterated | Needham | Buy |
| Apr-05-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Mar-01-18 | Reiterated | Needham | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Outperform |
| Sep-27-17 | Initiated | Northland Capital | Outperform |
| Feb-27-17 | Initiated | Needham | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| Sep-06-16 | Resumed | Lake Street | Buy |
| May-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Dec-10-15 | Initiated | Lake Street | Buy |
| Sep-23-15 | Reiterated | Leerink Partners | Outperform |
| Sep-02-15 | Initiated | BofA/Merrill | Buy |
| Aug-03-15 | Reiterated | Brean Capital | Buy |
| Jun-30-15 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-19-15 | Reiterated | Leerink Partners | Outperform |
| Aug-07-14 | Initiated | Noble Financial | Buy |
View All
Heron Therapeutics Inc Stock (HRTX) Latest News
Can Heron Therapeutics Inc. stock weather global recessionJuly 2025 PreEarnings & Risk Controlled Daily Plans - newser.com
Is Heron Therapeutics Inc. stock positioned well for digital economyJuly 2025 Summary & Daily Price Action Insights - newser.com
How Heron Therapeutics Inc. (AXD2) stock reacts to stronger dollar2025 Volume Leaders & Free Verified High Yield Trade Plans - newser.com
Heron Therapeutics Inc. stock prediction for this week2025 AllTime Highs & High Accuracy Swing Trade Signals - newser.com
Building trade automation scripts for Heron Therapeutics Inc.2025 Technical Overview & Verified Trade Idea Suggestions - newser.com
Published on: 2025-10-13 09:46:10 - newser.com
Why Heron Therapeutics Inc. stock could benefit from AI revolutionQuarterly Earnings Report & Weekly Watchlist for Hot Stocks - newser.com
Cyndeo Wealth Partners LLC Takes Position in Heron Therapeutics, Inc. $HRTX - MarketBeat
Is Heron Therapeutics Inc AXD2 a good long term investment - earlytimes.in
Heron Therapeutics (NASDAQ:HRTX) Upgraded at Zacks Research - Defense World
Heron Therapeutics (NASDAQ:HRTX) Stock Rating Upgraded by Zacks Research - MarketBeat
Chart based analysis of Heron Therapeutics Inc. trendsBear Alert & Momentum Based Trading Signals - newser.com
Heron Therapeutics (NASDAQ:HRTX) Earns "Sell (E+)" Rating from Weiss Ratings - MarketBeat
Why Heron Therapeutics Inc. is moving today2025 Trade Ideas & Fast Entry Momentum Trade Alerts - newser.com
Heron Therapeutics Inc. stock retracement – recovery analysisTrade Exit Summary & Entry Point Confirmation Alerts - newser.com
Why Heron Therapeutics Inc. stock remains on buy lists2025 AllTime Highs & Verified Short-Term Plans - newser.com
What data driven models say about Heron Therapeutics Inc.’s future - newser.com
Why Heron Therapeutics Inc. (AXD2) stock could be top winnerChart Signals & Smart Money Movement Tracker - newser.com
Heron Therapeutics, Inc. (HRTX) Stock Analysis: A 280% Potential Upside Beckons Investors - DirectorsTalk Interviews
Published on: 2025-10-01 09:34:43 - newser.com
Chart overlay techniques for tracking Heron Therapeutics Inc.Trade Analysis Summary & Reliable Price Breakout Alerts - newser.com
Why Heron Therapeutics Inc. (AXD2) stock signals breakout potentialJuly 2025 Earnings & Consistent Growth Equity Picks - newser.com
What analysts say about Heron Therapeutics Inc AXD2 stockFundamental Strength Indicators & Free Hedging Tactics for Volatile Markets - Early Times
Is Heron Therapeutics Inc a good long term investmentSector Rotation Strategies & Free Dynamic Capital Growth - Early Times
Heron Therapeutics Inc Stock (HRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Heron Therapeutics Inc Stock (HRTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morgan Adam | Director |
Aug 08 '25 |
Buy |
1.50 |
1,766,546 |
2,649,819 |
8,753,290 |
5.15%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):